11th Nils W. Svenningsen Memorial Lecture
Evidence-Based Neonatal Drug Therapy for Prevention of Bronchopulmonary Dysplasia in Very-Low-Birth-Weight InfantsSchmidt B.a, b · Roberts R.b · Millar D.c · Kirpalani H.a, b
aDepartment of Pediatrics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pa., USA; bDepartment of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont., Canada; cRoyal Maternity Hospital, Belfast, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Corticosteroids, intramuscular vitamin A and caffeine reduce the risk of bronchopulmonary dysplasia (BPD) in very-low-birth-weight infants. We compared the size of the beneficial drug effects on BPD and evaluated long-term drug safety by estimating the number needed to treat (NNT) and the number needed to harm (NNH) for the outcome of cerebral palsy (CP). When given prophylactically during the first 4 days of life, corticosteroids increase the risk of CP (NNH 22; 95% CI: 12–133). When prescribed between days 7 and 14, corticosteroids reduce the 28-day mortality rate in addition to reducing BPD. Their effect on CP remains uncertain: the limited data available are consistent with a best-case scenario (NNT 15) and a worst-case scenario (NNH 14). Although repeated intramuscular injections of vitamin A during the 1st month of life reduce BPD (NNT 12; 95% CI: 6–94), estimates for CP range from an NNT of 11 to an NNH of 33. Early use of caffeine reduces both BPD and CP. The NNT for BPD is 10 (95% CI: 7–16), while the NNT for CP is 34 (95% CI: 20–132). We conclude that caffeine is the drug of choice for the prevention of BPD in very-low-birth-weight infants. Corticosteroids should be avoided during the first few days of life. However, when given during the 2nd week of life to infants at high risk of BPD corticosteroids may have important short- and long-term benefits. These should be urgently confirmed or refuted in well-designed controlled trials.
© 2008 S. Karger AG, Basel
- Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM: Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527–532.
- Davis PG, Thorpe K, Roberts R, Schmidt B, Doyle LW, Kirpalani H; Trial Indomethacin Prophylaxis in Preterms Investigators: Evaluating ‘old’ definitions for the ‘new’ bronchopulmonary dysplasia. J Pediatr 2002;140:555–560.
- Jobe AH, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–1729.
- Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A: Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003;23:451–456.
- Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA: Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999;340:1962–1968.
- Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group: Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112–2121.
- Kugelman A, Reichman B, Chistyakov I, Boyko V, Levitski O, Lerner-Geva L, Riskin A, Bader D; Israel Neonatal Network: Postdischarge infant mortality among very low birth weight infants: a population-based study. Pediatrics 2007;120:e788–e794.
- Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators: Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003;289:1124–1129.
- Anderson PJ, Doyle LW: Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol 2006;30:227–232.
- Doyle LW; Victorian Infant Collaborative Study Group: Respiratory function at age 8–9 years in extremely low birthweight/very preterm children born in Victoria in 1991–1992. Pediatr Pulmonol 2006;41:570–576.
- Shinwell ES, Lerner-Geva L, Lusky A, Reichman B: Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007;92:F30–F33.
- Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, Richardson DK: Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005;146:469–473.
- Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G; National Institute of Child Health and Human Development Neonatal Research Network: Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004;114:1305–1311.
- Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ, Richardson DK: Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. J Pediatr 2004;144:799–803.
Halliday HL, Ehrenkranz RA, Doyle LW: Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001146.
Halliday HL, Ehrenkranz RA, Doyle LW: Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001144.
Darlow BA, Graham PJ: Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007;4:CD000501.
- Millar D, Schmidt B: Controversies surrounding xanthine therapy. Semin Neonatol 2004;9:239–244.
- Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group: Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893–1902.
- Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, Carlo WA; National Institute of Child Health and Human Development Neonatal Research Network: Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 2005;115:e249–e254.
- Bender R: Calculating confidence intervals for the number needed to treat. Control Clin Trials 2001;22:102–110.
- Normand SL: Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999;18:321–359.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.